CervoMed Inc. financial data

Symbol
CRVO on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 07 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 13% % 18%
Return On Equity 130% % 2223%
Return On Assets -68% % -71%
Operating Margin -442% % -230%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9,252,719 shares 12%
Common Stock, Shares, Outstanding 9,252,719 shares 12%
Entity Public Float $91,600,000 USD
Common Stock, Value, Issued $9,252 USD 12%
Weighted Average Number of Shares Outstanding, Basic 9,252,719 shares 6.3%
Weighted Average Number of Shares Outstanding, Diluted 8,702,764 shares 131%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $6,159,786 USD -39%
Research and Development Expense $23,073,462 USD 58%
General and Administrative Expense $10,290,503 USD 15%
Operating Income (Loss) $27,204,179 USD -102%
Nonoperating Income (Expense) $1,619,188 USD 6.6%
Net Income (Loss) Attributable to Parent $25,584,991 USD -114%
Earnings Per Share, Basic -2 USD/shares -368%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $9,437,400 USD 22%
Marketable Securities, Current $17,856,688 USD -54%
Cash, Cash Equivalents, and Short-term Investments $27,300,000 USD
Other Assets, Current $49,806 USD -33%
Assets, Current $30,610,778 USD -37%
Other Assets, Noncurrent $0 USD -100%
Assets $30,610,778 USD -37%
Accounts Payable, Current $1,349,219 USD 25%
Employee-related Liabilities, Current $1,012,184 USD 37%
Liabilities $4,599,314 USD 42%
Accumulated Other Comprehensive Income (Loss), Net of Tax $5,824 USD -95%
Retained Earnings (Accumulated Deficit) $89,610,561 USD -40%
Stockholders' Equity Attributable to Parent $26,011,464 USD -43%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $5,336,378 USD
Liabilities and Equity $30,610,778 USD -37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,894,359 USD -174%
Net Cash Provided by (Used in) Investing Activities $5,396,577 USD
Common Stock, Shares Authorized 1,000,000,000 shares 0%
Common Stock, Shares, Issued 9,252,719 shares 12%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,502,218 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,501,714 USD 65%
Deferred Tax Assets, Gross $18,931,779 USD 33%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $25,702,329 USD -210%
Deferred Tax Assets, Operating Loss Carryforwards $10,417,666 USD -0.74%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30,000,000 shares
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $115,606,949 USD 5.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $18,557,844 USD 32%
Share-based Payment Arrangement, Expense $1,487,610 USD 21%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares